|1.||Harris, Kevin P G: 1 article (04/2004)|
|2.||Patel, Samita R: 1 article (04/2004)|
|3.||Pawluczyk, Izabella Z A: 1 article (04/2004)|
|4.||Ashikaga, Takashi: 1 article (07/2003)|
|5.||Ohta, Seiko: 1 article (07/2003)|
|6.||Sakita, Sin-Ya: 1 article (07/2003)|
|7.||Kishi, Yukio: 1 article (07/2003)|
|8.||Isobe, Mitsuaki: 1 article (07/2003)|
|9.||Kasuya, Natsuko: 1 article (07/2003)|
|10.||Nabeshima, Toshitaka: 1 article (06/2003)|
07/01/2001 - "Pharmacokinetic-pharmacodynamic model for perindoprilat regional haemodynamic effects in healthy volunteers and in congestive heart failure patients."
01/01/1994 - "[The effect of perindoprilat on the cardiovascular system of rats with heart failure]."
01/01/1994 - "The effect of intravenous perindoprilat, 0.5 mg/kg, on regional blood flow (radioactive microspheres, 15 microns), systemic hemodynamics, vein tone and cardiac functions was evaluated in conscious rats with congestive heart failure. "
04/01/1993 - "Double blind controlled study of low dose intravenous perindoprilat or enalaprilat infusion in elderly patients with heart failure."
01/01/1994 - "Perindoprilat unchanged the mean circulatory filling pressure in sham-operated animals and decreased it by 15% in rats with heart failure."
|2.||Renal Insufficiency (Renal Failure)
08/01/1991 - "This effect of renal failure on the pharmacodynamics of perindoprilat was more pronounced than its influence on perindoprilat kinetics. "
08/01/1991 - "4 The mean area under the serum concentration-time curve of the active metabolite perindoprilat increased from 93 ng ml-1 h in subjects with normal renal function to 1106 ng ml-1 in patients with severe renal failure, whereas its half-life varied from 5.0 to 27.4 h. "
01/01/1991 - "As it has been shown that the kinetics of perindoprilat are mainly affected by renal insufficiency, a dosage reduction is therefore recommended on initiation of treatment in elderly patients and in those with renal failure according to the degree of renal failure. "
06/01/2003 - "Elimination kinetics of quinaprilat and perindoprilat in hypertensive patients with renal failure on haemodialysis."
08/01/1991 - "8 In view of the important influence of renal impairment on the elimination and action of the active substance perindoprilat, a dosage reduction of perindopril is proposed in in patients with renal failure.(ABSTRACT TRUNCATED AT 250 WORDS)"
06/01/2001 - "Groups 3 and 4 had infarct sizes not statistically different from group 1. However, combining perindoprilat with subthreshold PC resulted in a significant limitation of the infarction (18.4+/-3.1% p < 0.05), comparable with group 2. This is the first study to show that ACE inhibition can augment a mild ischemic stimulus to induce a protected state 24 h later."
02/01/1994 - "The aims were: (1) to study the acute effects of captopril on the action potential characteristics of ventricular fibres from the normal rat, (2) to compare the effects of captopril with those of perindoprilat, a non-thiol angiotensin I converting enzyme (ACE) inhibitor, (3) to determine the electrophysiological properties of the peptide substrates of converting enzyme, bradykinin and angiotensin I, and (4) to investigate whether the effects of captopril occurring in the healthy heart also occur in two models of ventricular hypertrophy. "
|3.||Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
|8.||Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
|1.||Blood Component Removal (Apheresis)